We examine recent clinical trial data and observational evidence following treatment with SGLT2 inhibitors in patients with T2D and CKD, with a focus on their effects on kidney function, cardiovascular (CV) and HF outcomes and safety in this often-challenging setting. The gene discussed is SLC5A2; the disease is hydrops fetalis.